BLFS
What one share of BioLife Solutions holds
Electromedical and Electrotherapeutic Apparatus
We are a life sciences company that develops, manufactures, and markets bioproduction products and services which are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry.
BioLife Solutions’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.21 |
|---|---|
| Profit | $1.20 |
| Capex (buildings and equipment) | $0.18 |
| Free cash flow | $0.17 |
| Cash and investments | $0.49 |
| Debt | $0.00 |
| Book value | $8.59 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.65 | −$0.54 | $0.01 | −$0.35 | — | $0.25 |
| 2017 | $0.83 | −$0.21 | $0.01 | $0.03 | — | −$0.68 |
| 2018 | $0.91 | −$1.56 | $0.02 | $0.09 | — | $0.79 |
| 2019 | $1.41 | −$0.09 | $0.03 | $0.03 | — | $2.08 |
| 2020 | $1.76 | −$0.06 | $0.07 | $0.17 | — | $6.19 |
| 2021 | $3.09 | −$0.23 | $0.22 | −$0.34 | — | $11.43 |
| 2022 | $1.77 | −$3.25 | $0.24 | −$0.44 | — | $8.50 |
| 2023 | $1.56 | −$1.56 | $0.15 | −$0.43 | — | $7.48 |
| 2024 | $1.62 | −$0.44 | $0.07 | $0.11 | — | $7.44 |
| 2025 | $1.98 | −$0.10 | $0.19 | $0.22 | — | $7.72 |